Introduction: Malignant pleural mesothelioma is an aggressive malignancy with limited systemic therapy options. Promising results have been reported with use of anti-programmed cell death 1 therapy; however, its benefits appear to be confined to a subgroup of patients. Microsatellite instability (MSI) results from the inactivation of DNA mismatch repair genes and results in a high tumor mutational burden, a phenomenon that has not been seen with mesothelioma. MSI and protein absence have been shown to correlate in colorectal cancer, such that most centers have adopted immunohistochemistry (IHC) to screen for MSI-high colorectal cancers. We profiled a large cohort of patients with mesothelioma to determine the rate of negative IHC staining results the four common mismatch repair proteins.
Introduction
Microsatellite instability (MSI) arises from inactivation of any of several mismatch repair (MMR) genesmutL homolog 1 gene (MLH1); PMS1 homolog 2, mismatch repair system component gene (PMS2); mutS homolog 2 gene (MSH2); and mutS homolog 6 gene (MSH6)-resulting in failure to repair the routine errors that occur during replication of short repeats in DNA sequences. 1, 2 These translated proteins form heterodimers that repair DNA damage, with the most common and relevant to tumorigenesis being mutL homolog 1 (MLH1)/PMS1 homolog 2, mismatch repair system component (PMS2) and mutS homolog 2 (MSH2)/mutS homolog 6 (MSH6). 3 Immunohistochemistry (IHC) for MMR has a specificity of 88.8%, which is comparable to the specificity of 90.2% with MSI testing by polymerase chain reaction, making IHC a valid screening method for deficient MMR. 4 Deleterious germline mutations occur in the MMR genes in families with Lynch syndrome, in which a second hit in the unaffected wild-type allele through loss of heterozygosity, mutation, or hypermethylation leads to cancers. 3 The classical association of Lynch syndrome is the development of colorectal cancers; however, it is also linked with other cancer types, especially endometrial cancer, but also including ovarian, gastric, and prostate cancers and glioblastoma. 5 It is also now recognized that MSI can occur in the absence of germline MMR mutations on account of epigenetic inactivation of MLH1 by promoter methylation. 6 Determining the MSI status in tumors has become clinically relevant because of its prognostic and predictive implications. From a prognostic value, mutations arising from MSI have been observed to drive tumorigenesis by inactivating tumor suppressor genes. 7 MSIhigh colorectal carcinomas have improved clinical outcomes, such that chemotherapy is not recommended for stage II MSI-high colon cancers. 8 Moreover, MSI-high tumors elicit a high tumor mutational burden and are associated with responses to programmed cell death 1 (PD-1) inhibitors, presumably from a higher neoantigen load leading to enhanced T-lymphocyte recognition. 9 Malignant pleural mesothelioma (MPM) is an aggressive thoracic malignancy with a median survival of 12 months. 10 After platinum doublet chemotherapy with an anti-vascular endothelial growth factor agent, there is no standard of care second-line systemic option. The Keynote-028 phase 1B study included a cohort of 25 heavily pretreated patients with MPM with a level of programmed death ligand 1 (PD-L1) staining higher than 1%. Pembrolizumab, an anti-PD-1 antibody, resulted in an objective response rate in five patients (20%) and disease stability in 13 patients (52%), with an associated median response duration of 12 months. 11 Although encouraging, this response rate was modest given the treated population, which was biomarker and biology selected (32% with two or more lines of therapy). A subsequent retrospective study of 46 PD-L1-unselected patients who had received a median of two previous lines of therapy and had been treated with pembrolizumab showed a similar objective response rate of 15%, with the median duration of response not yet reached. 12 We hypothesized that this minor group of anti-PD-1 responders might have either a sporadic or germline defect in MMR. There are only two reported cases in the literature of MSI in MPM 13 and only one report of a patient with peritoneal mesothelioma who was found to have a defect in MMR (loss of MLH1/PMS2).
14 We sought to profile a large cohort of MPM archival tumor samples to investigate whether there was any loss of MMR proteins suggesting an MSI-high phenotype.
Methods
Under a human research ethics committee-approved protocol, archival tissue specimens from 335 patients that were collected from December 1989 to December 2013 were obtained from the Austin Hospital pathology department. All patients had histological confirmation of MPM by a pathologist. Clinicopathological information, including age, sex, smoking history, asbestos exposure, and histological subtype, was gathered.
Tissue microarrays (TMAs) were created by using a Mark II TMA arrayer (Beecher Instruments, Sun Prairie, WI) from formalin-fixed, paraffin embedded blocks with three cores per patient, each with a size of 1 Â 1. Bound primary antibodies were detected by using a Ventana UltraView Universal DAB detection kit (Ventana Medical Systems, Tucson, AZ) for MLH1, MSH2, and MSH6 and a Ventana Optiview DAB IHC Detection Kit (Ventana) for PMS2. Slides were scanned by using an Aperio ScanScope XT system (Leica Biosystems, Nussloch, Germany). Normal expression was defined as nuclear staining within tumor cells, with infiltrating lymphocytes used as a positive internal control. Negative protein expression was defined as complete absence of nuclear staining within tumor cells in the context of positive labeling in internal noncancerous tissue.
Samples that were negative for MMR according to IHC staining were analyzed for MSI. DNA was isolated from two areas on each TMA, one containing tumor and the other containing nonmalignant epithelial tissue, by using the DNeasy Blood and Tissue kit (Qiagen, Valencia, Ca). Subsequent analysis was performed by using the MSI Analysis System (version 1.2, Promega). This system consists of five mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24, and MONO-27) for MSI determination and two pentanucleotide repeat markers (Penta C and Penta D) for sample identification. Samples were tested according to the manufacturer's instructions.
PD-L1 (clone E1L3N [Cell Signalling Technology, Danvers, MA]) was used to stain the TMAs and was previously reported. 15 The result of PD-L1 staining was considered negative if absent, positive if the level of membranous staining was at least 5% (regardless of intensity), and highly positive if there was at least 50% moderate or intense staining.
Results
A total of 335 patients with MPM were included in our analysis (Table 1) . Their ages ranged from 24 to 87 years, with a mean age of 66 years. The male-to-female ratio was 5:1, 56% of the patients were smokers, and 74% were exposed to asbestos. The histopathological subsets included the 65% of the study patients with epithelioid tumors, 13% with sarcomatoid tumors, and 22% with biphasic tumors.
The results of all four IHC assays for MMR proteins (MLH1, PMS2, MSH2, and MSH6) were positive in 329 of 335 cases (98%). An example of a positive stain is shown in Figure 1 . Negative staining of at least one MMR protein was seen in six cases, which were subsequently analyzed for MSI and confirmed to be negative (Fig. 2) .
All of these six patients were male and had the epithelioid histological subtype; their age ranged from 49 to 79 years ( Table 2 ). None had a significant family history of malignancies and all died without receiving immunotherapy. Of interest, in these six cases, PD-L1 staining was negative in five patients and at a level less than 5% in one patient. The patterns of MMR loss are as shown in Figure 2 .
PD-L1 findings from 319 of the TMA samples were reported previously. 15 The median overall survival was worse in patients with high PD-L1 positivity regardless of histological subtype, as shown (Table 3) . 
Discussion
In recent years, our knowledge of the genetic implications of cancers has increased substantially. Analyzing tumor samples for MSI has become crucial from both a prognostic and predictive perspective in the context of increased activity seen with anti-PD-1 antibodies in MSIhigh tumors. 9 Lynch syndrome, which is characterized by germline MMR mutations, includes a constellation of cancers, notably, gastrointestinal and uterine cancers. An interesting report from a large genetic database set from Memorial Sloan Kettering Institute Cancer Center found four unusual tumors with deficient MMR, including peritoneal mesothelioma, acinar pancreatic carcinoma, pancreatic endocrine neoplasm, and adrenal cortical carcinoma.
14 Intriguingly, from a recent analysis of 83 mesothelioma samples in The Cancer Genome Atlas database, two patients were found to be MSI high. 13 Given that MPM is a rare tumor with limited treatment options, the promising, albeit modest objective response rate seen with anti-PD-1 therapy from Keynote-028 is intriguing. We sought to understand whether a possible explanation for some of the responses was MSI. As such, we retrospectively reviewed our large MPM archival TMAs for the presence of MMR by IHC.
Although we found six cases with deficient MMR, none of the samples were proved to have MSI. MMR IHC and MSI analysis by polymerase chain reaction have shown a high concordance (>95%) across a variety of tumor types. 16, 17 Potential limitations of our study are the limited tumor sample in TMAs and heterogeneous IHC staining across tumor samples with a risk of falsenegative results.
As previously reported by us and two other groups, high PD-L1 positivity is associated with a worse median overall survival in MPM. 15, 18, 19 A recent meta-analysis showed that PD-L1 overexpression was associated with a worse 5-year outcome in patients with gastric cancer, esophageal cancer, and colorectal cancer but a better survival in patients with melanoma, NSCLC, and oral squamous cell carcinoma. 20 The reasons for this are unclear but could be attributable to the heterogeneity of the studies across tumor histologic subtypes, presence of activating mutations, postsurgical versus advanced-stage disease, and use of different PD-L1 antibodies and cutoffs.
An important question that we were hoping to address is whether there could be a potential correlation between MSI-high disease, PD-L1, and overall survival. MSI-high colorectal cancers display a more favorable clinical course, and patients with stage 2 or 3 disease have a lower recurrence rate than do patients with MMR-proficient tumors. 21 A potential reason for this is that MSI-high tumor cells are constantly undergoing immune surveillance and immuneediting by CD8 T lymphocytes in the context of a high tumor mutational burden. Eventually, there is upregulation of PD-L1 in the tumor cells, which leads to immune evasion and cancer progression. There was a recent report that PD-L1 expression in MSI-high gastric cancer was independently associated with a longer survival time. 22 This is an important finding, as it can assist in identifying potential patients who are more likely to respond to anti-PD-1 therapy. In our study, were unable to assess responses to immune checkpoint inhibitors, as none of the patients with deficient MMR had been treated with an immune checkpoint inhibitor.
MPM is largely an asbestos-driven cancer, and recent whole exome studies have confirmed a lower mutational burden than with other tumors such as melanoma and lung cancer. 23 In our series, 74% of patients had asbestos exposure, and the mean age was 66 years, with a good representation of MPM patients. Among the six patients who had MMR IHC loss, none had a family history of multiple malignancies. In the case series published by Karamurzin et al., one patient with MMRdeficient peritoneal mesothelioma was identified; the patient's mesothelioma was diagnosed when he was 56 years old, and he had a history of colon cancer at 24 years of age and two first-degree relatives with colon cancer.
14 Given our findings in the context of this one reported patient with deficient MMR and the two cases of MSI in The Cancer Genome Atlas database analysis, it would be prudent to consider targeted MMR IHC testing and confirmatory follow-up MSI testing in patients with MPM with both an individual history and family history of cancers rather than to perform routine testing in all patients, given the very low yield.
Conclusion
Our data suggest that MSI is rare in mesothelioma, and they are in agreement with the low mutational burden seen in other studies. To our knowledge, this is the largest series of MPM patients screened for MMR. Our findings are important, as they suggest that patients with MPM who respond to anti-PD-1 therapies are likely to have other mechanisms of action, such as high tumor PD-L1 expression and an enriched immune microenvironment, which warrants further study. However, targeted MSI testing in patients with MPM with an individual and family history of cancers could be informative in helping with decision making on immune checkpoint inhibitor therapy.
